• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular touts patient experience data for Dextenza implant

March 15, 2017 By Sarah Faulkner

Ocular touts patient experience data for Dextenza implantOcular Therapeutix (NSDQ:OCUL) touted data today from a patient experience study of its Dextenza post-surgical pain relief implant. The study was published in Patient Preference and Adherence. 

The Bedford, Mass.-based company’s hydrogel plug, inserted into a patient’s tear duct, is designed to deliver a sustained dose of dexamethasone over 4 weeks following ophthalmic surgery. After the treatment is complete, the plug resorbs and exits the nasolacrimal system without the need for a removal procedure.

The retrospective patient experience study enrolled 25 patients who received treatment in the company’s Phase III trial of Dextenza. According to the data, all of the patients reported that the insert was comfortable and 96% felt that it was extremely or very convenient compared to topical eye drops. Patients were very satisfied with the product, with 88% saying that they would request Dextenza if they were to have cataract surgery again.

“We are encouraged by the experiences these patients shared, which add another dimension to the clinical results achieved in the Phase III clinical trials,” chief medical officer Dr. Jonathan Talamo said in prepared remarks. “If approved, we believe that Dextenza, which incorporates the company’s proprietary hydrogel platform technology, will offer an attractive alternative to the current post-operative standard of care of steroid eye drops for those recovering from ophthalmic surgery.”

Last week, Ocular shares fell after the biopharmaceutical company missed earnings expectations, but beat sales estimates on Wall Street with its 4th quarter results.

The company posted losses of -$-12.8 million, or -52¢ per share, on sales of $0.5 million for the 3 months ended Dec. 31, for bottom-line loss of -20.5% on sales growth of 17% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -52¢, behind consensus on The Street, where analysts were looking for sales of $0.48 million.

In January, Ocular resubmitted a New Drug Application to the FDA for Dextenza.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Hydrogels, Optical/Ophthalmic, Wall Street Beat Tagged With: Ocular Therapeutix

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS